An Open-Label, Single-Dose Study to Investigate the Influence of Renal Insufficiency on the Pharmacokinetics of MK-7264
Phase of Trial: Phase I
Latest Information Update: 22 Sep 2017
At a glance
- Drugs Gefapixant (Primary)
- Indications Asthma; Cough; Interstitial cystitis; Musculoskeletal pain
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 19 Sep 2017 Status changed from active, no longer recruiting to completed.
- 04 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Aug 2017 Planned primary completion date changed from 6 Oct 2017 to 26 Sep 2017.